View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Üllői út 26., 1085
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 3 Universitätsklinikum des Saarlandes, UKS, Homburg/Saar, Deutschland
Open access

Absztrakt:

Jelen összefoglalóban a szemfelszíni laphám-neoplasiáról való ismereteket összegzik a szerzők, beleértve ezen daganattípus epidemiológiáját, etiológiáját, patológiáját, klinikai megjelenését és kezelését. A conjunctivalis intraepithelialis neoplasiával és az invazív laphámrákkal kapcsolatos közleményeket tekintették át a szerzők néhány saját eset bemutatásával, amelyek alapján olyan alapvető írást szeretnének közölni, amely részletesen taglalja és bemutatja jelenlegi ismereteinket a szemfelszíni laphám-neoplasiáról. A szemfelszíni laphám-neoplasia a leggyakoribb szemfelszíni malignus tumor, illetve a choroidealis melanoma malignumot és a lymphomát követően a harmadik leggyakoribb okuláris malignoma. Alacsony malignitási potenciálja ellenére előrehaladott stádiumban jelentős látásromláshoz vezethet, sőt akár a szemgolyó eltávolításának szükségessége mellett távoli metasztázis kialakulásakor az életet is veszélyeztetheti. Gyakori recidívaképződés miatt kezelésében elengedhetetlen az intra- és posztoperatív adjuváns kezelési módok ismerete és alkalmazása, valamint a rendszeres kontrollvizsgálat. A szemfelszíni laphám-neoplasia felismerése és adekvát kezelése elengedhetetlen ezen tumortípus progressziójának elkerülésében és a recidíva kialakulásának megelőzésében. Orv Hetil. 2017; 158(51): 2011–2022.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Lee GA, Hirst LW. Incidence of ocular surface epithelial dysplasia in metropolitan Brisbane. A 10-year survey. Arch Ophthalmol. 1992; 110: 525–527.

  • 2

    Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea 2003; 22: 687–704.

  • 3

    Lugossy G. Precancerous conditions of the bulbar conjunctiva. Am J Ophthalmol. 1956; 42: 107–112.

  • 4

    Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol. 1995; 39: 429–450.

  • 5

    Templeton AC. Tumors of the eye and adnexa in Africans of Uganda. Cancer 1967; 20: 1689–1698.

  • 6

    Sun EC, Fears TR, Goedert JJ. Epidemiology of squamous cell conjunctival cancer. Cancer Epidemiol Biomarkers Prev. 1997; 6: 73–77.

  • 7

    Yang J, Foster CS. Squamous cell carcinoma of the conjunctiva. Int Ophthalmol Clin. 1997; 37: 73–85.

  • 8

    Gichuhi S, Sagoo MS, Weiss HA, et al. Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health 2013; 18: 1424–1443.

  • 9

    Hertle RW, Durso F, Metzler JP, et al. Epibulbar squamous cell carcinomas in brothers with xeroderma pigmentosa. J Pediatr Ophthalmol Strabismus 1991; 28: 350–353.

  • 10

    Kiire CA, Dhillon B. The aetiology and associations of conjunctival intraepithelial neoplasia. Br J Ophthalmol. 2006; 90: 109–113.

  • 11

    Pater MM, Dunne J, Hogan G, et al. Human papillomavirus types 16 and 18 sequences in early cervical neoplasia. Virology 1986; 155: 13–18.

  • 12

    McDonnell JM, Mayr AJ, Martin WJ. DNA of human papillomavirus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea. N Engl J Med. 1989; 320: 1442–1446.

  • 13

    McDonnell JM, McDonnell PJ, Sun YY. Human papillomavirus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasia. Invest Ophthalmol Vis Sci. 1992; 33: 184–189.

  • 14

    Waddell K, Magyezi J, Bousarghin L, et al. Antibodies against human papillomavirus type 16 (HPV-16) and conjunctival squamous cell neoplasia in Uganda. Br J Cancer 2003; 88: 2002–2003.

  • 15

    Ateenyi-Agaba C. Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet 1995; 345: 695–696.

  • 16

    Newton R. A review of the aetiology of squamous cell carcinoma of the conjunctiva. Br J Cancer 1996; 74: 1511–1513.

  • 17

    Waddell KM, Lewallen S, Lucas SB, et al. Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi. Br J Ophthalmol. 1996; 80: 503–508.

  • 18

    Karp CL, Scott IU, Chang TS, et al. Conjunctival intraepithelial neoplasia. A possible marker for human immunodeficiency virus infection? Arch Ophthalmol. 1996; 114: 257–261.

  • 19

    Wilson FM 2nd. Rose bengal staining of epibulbar squamous neoplasms. Ophthalmic Surg. 1976; 7: 21–23.

  • 20

    McKelvie PA, Daniell M, McNab A, et al. Squamous cell carcinoma of the conjunctiva: a series of 26 cases. Br J Ophthalmol. 2002; 86: 168–173.

  • 21

    De Potter P, Shields CL, Shields JA, et al. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993; 77: 624–630.

  • 22

    Nelson KD, McSoley JJ. Clinical findings and management of conjunctival intraepithelial neoplasia. Optometry 2011; 82: 15–21.

  • 23

    Tóth J. Ophthalmic pathology. In: Schaff Z. (ed.) Pathology. [Szempatológia. In: Schaff Z. (szerk.) Patológia.] Medicina Könyvkiadó, Budapest, 2004; pp. 1292–1315. [Hungarian]

  • 24

    Grossniklaus HE, Green WR, Luckenbach M, et al. Conjunctival lesions in adults. A clinical and histopathologic review. Cornea 1987; 6: 78–116.

  • 25

    Yeatts RP, Ford JG, Stanton CA, et al. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology 1995; 102: 1338–1344.

  • 26

    Tole DM, McKelvie PA, Daniell M. Reliability of impression cytology for the diagnosis of ocular surface squamous neoplasia employing the Biopore membrane. Br J Ophthalmol. 2001; 85: 154–158.

  • 27

    Nolan GR, Hirst LW, Wright RG, et al. Application of impression cytology to the diagnosis of conjunctival neoplasms. Diagn Cytopathol. 1994; 11: 246–249.

  • 28

    Edge SB, Byrd DR, Compton CC, et al. Carcinoma of the conjunctiva. In: Edge SE, Byrd DR, Carducci MA, et al. (eds.) AJCC cancer staging manual. 7th ed. Springer, New York, 2009; pp. 531–537.

  • 29

    Kenawy N, Garrick A, Heimann H, et al. Conjunctival squamous cell neoplasia: the Liverpool Ocular Oncology Centre experience. Graefes Arch Clin Exp Ophthalmol. 2015; 253: 143–150.

  • 30

    Sarici AM, Arvas S, Pazarli H. Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 2013; 251: 2201–2204.

  • 31

    Shields CL, Kaliki S, Kim HJ, et al. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification. Cornea 2013; 32: 248–256.

  • 32

    Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol. 1997; 115: 808–815.

  • 33

    Tunc M, Char DH, Crawford B, et al. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol. 1999; 83: 98–103.

  • 34

    Tabin G, Levin S, Snibson G, et al. Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology 1997; 104: 485–492.

  • 35

    Khokhar S, Soni A, Singh Sethi H, et al. Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea 2002; 21: 189–191.

  • 36

    Siganos CS, Kozobolis VP, Christodoulakis EV. The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea 2002; 21: 12–16.

  • 37

    Módis L, Tóth E, Berta A. Surgical treatment of ocular surface diseases. [A szemfelszín betegségeinek sebészi kezelése.] Orv Hetil. 2009; 150: 1599–1606. [Hungarian]

  • 38

    Bucher F, Parthasarathy A, Bergua A, et al. Topical ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol. 2014; 92: 143–148.

  • 39

    Asena L, Dursun Altinors D. Topical bevacizumab for the treatment of ocular surface squamous neoplasia. J Ocul Pharmacol Ther. 2015; 31: 487–490.

  • 40

    Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol. 2010; 94: 555–558.

  • 41

    Bahrami B, Greenwell T, Muecke JS. Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Clin Exp Ophthalmol. 2014; 42: 317–322.

  • 42

    Galor A, Karp CL, Chhabra S, et al. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol. 2010; 94: 551–554.

  • 43

    Karp CL, Galor A, Chhabra S, et al. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 2010; 117: 2241–2246.

  • 44

    Esquenazi S, Fry CL, Holley E. Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol. 2005; 89: 1221.

  • 45

    Lecuona K, Stannard C, Hart G, et al. The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV. Br J Ophthalmol. 2015; 99: 1158–1161.

  • 46

    Hirst LW. Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution. Ophthalmology 2007; 114: 976–982.

  • 47

    Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013; 24: 336–342.

  • 48

    Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol. 2000; 84: 268–272.

  • 49

    Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000; 107: 2190–2195.

  • 50

    Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol. 2017; 101: 1094–1099.

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.

2019  
Total Cites
WoS
1 085
Impact Factor 0,497
Impact Factor
without
Journal Self Cites
0,212
5 Year
Impact Factor
0,396
Immediacy
Index
0,126
Citable
Items
247
Total
Articles
176
Total
Reviews
71
Cited
Half-Life
6,1
Citing
Half-Life
7,3
Eigenfactor
Score
0,00071
Article Influence
Score
0,045
% Articles
in
Citable Items
71,26
Normalized
Eigenfactor
0,08759
Average
IF
Percentile
10,606
Scimago
H-index
20
Scimago
Journal Rank
0,176
Scopus
Scite Score
864/1178=0,4
Scopus
Scite Score Rank
General Medicine 267/529 (Q3)
Scopus
SNIP
0,254
Acceptance
Rate
73%

 

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu